Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LRG001
MIFTS: 47

Large Cell Carcinoma

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Large Cell Carcinoma

About this section

MalaCards integrated aliases for Large Cell Carcinoma:

Name: Large Cell Carcinoma 12 15
Carcinoma, Large Cell 45 74
Carcinoma Large Cell 56

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases Rare diseases
Anatomical: Skin diseases Respiratory diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4552
MeSH 45 D018287
NCIt 51 C3780
SNOMED-CT 69 22687000
UMLS 74 C0206704
Sources

Summaries for Large Cell Carcinoma

About this section
Disease Ontology : 12 A carcinoma that is composed of large, monotonous rounded or overtly polygonal-shaped cells with abundant cytoplasm.

MalaCards based summary : Large Cell Carcinoma, also known as carcinoma, large cell, is related to pleomorphic carcinoma and large cell neuroendocrine carcinoma. An important gene associated with Large Cell Carcinoma is SYP (Synaptophysin), and among its related pathways/superpathways are Neuroscience and L1CAM interactions. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and thyroid, and related phenotypes are cellular and behavior/neurological

Sources

Related Diseases for Large Cell Carcinoma

About this section

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Cell Type Cancer
Basal Cell Carcinoma Large Cell Carcinoma
Basal Cell Carcinoma, Multiple

Diseases related to Large Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 263)
# Related Disease Score Top Affiliating Genes
1 pleomorphic carcinoma 32.2 EGFR KRT7 NKX2-1
2 large cell neuroendocrine carcinoma 31.2 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
3 adenocarcinoma 30.5 EGFR FGFR1 ROS1 STK11
4 pulmonary large cell neuroendocrine carcinoma 29.9 CHGA ENO2 ROS1 SYP
5 squamous cell carcinoma 29.8 EGFR PTHLH STK11 TP63
6 lung squamous cell carcinoma 29.1 EGFR FGFR1 PTHLH ROS1 TP63
7 small cell carcinoma 29.1 CHGA EGFR ENO2 KRT7 NCAM1 NKX2-1
8 small cell cancer of the lung 28.2 CEACAM5 CHGA EGFR ENO2 KRT7 NCAM1
9 lung cancer susceptibility 3 27.9 CEACAM5 EGFR KRT7 NKX2-1 SFTPB STK11
10 lung cancer 26.8 CEACAM5 CHGA EGFR ENO2 FGFR1 KRT7
11 lung large cell carcinoma 12.6
12 large cell carcinoma with rhabdoid phenotype 12.4
13 thymus large cell carcinoma 12.3
14 lung occult large cell carcinoma 12.2
15 lung mixed small cell and squamous cell carcinoma 11.2
16 large cell keratinizing variant squamous cell breast carcinoma 11.2
17 gastrointestinal neuroendocrine tumor 10.5 CHGA SYP
18 rosette-forming glioneuronal tumor 10.5 FGFR1 SYP
19 peritoneal serous adenocarcinoma 10.5 CHGA SYP
20 cellular ependymoma 10.5 CHGA SYP
21 ovarian germ cell cancer 10.5 KRT7 NKX2-1
22 solid adenocarcinoma with mucin production 10.5 KRT7 NKX2-1
23 acinar cell cystadenocarcinoma 10.5 CHGA SYP
24 olfactory groove meningioma 10.5 CHGA SYP
25 papillary serous adenocarcinoma 10.5 KRT7 NKX2-1
26 gastrointestinal neuroendocrine benign tumor 10.5 CHGA TP63
27 chordoid meningioma 10.5 CHGA SYP
28 papillary adenoma 10.5 KRT7 NKX2-1
29 gastric neuroendocrine neoplasm 10.5 CHGA TP63
30 primary hepatic neuroendocrine carcinoma 10.5 CHGA SYP
31 ovarian germ cell teratoma 10.5 KRT7 NKX2-1
32 lung acinar adenocarcinoma 10.5 KRT7 NKX2-1
33 acute thyroiditis 10.4 CHGA ENO2
34 cribriform carcinoma 10.4 KRT7 TP63
35 pancreatic somatostatinoma 10.4 ENO2 SYP
36 central nervous system primitive neuroectodermal neoplasm 10.4 ENO2 SYP
37 melanotic neuroectodermal tumor 10.4 ENO2 SYP
38 lung oat cell carcinoma 10.4 CHGA ENO2
39 cerebral ventricle cancer 10.4 ENO2 SYP
40 cerebral neuroblastoma 10.4 ENO2 SYP
41 cerebellum cancer 10.4 ENO2 SYP
42 epithelioid malignant peripheral nerve sheath tumor 10.4 CHGA ENO2
43 extraosseous chondrosarcoma 10.4 ENO2 SYP
44 goblet cell carcinoid 10.4 CHGA ENO2
45 subependymal glioma 10.4 ENO2 SYP
46 benign ependymoma 10.4 ENO2 SYP
47 pineal gland cancer 10.4 ENO2 SYP
48 clear cell ependymoma 10.4 ENO2 SYP
49 malignant teratoma 10.4 ENO2 SYP
50 astroblastoma 10.4 ENO2 SYP

Graphical network of the top 20 diseases related to Large Cell Carcinoma:



Diseases related to Large Cell Carcinoma
Sources

Symptoms & Phenotypes for Large Cell Carcinoma

About this section

MGI Mouse Phenotypes related to Large Cell Carcinoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 DSC3 EGFR ENO2 FGFR1 KRT7 NCAM1
2 behavior/neurological MP:0005386 10.19 ENO2 FGFR1 KRT5 NCAM1 NKX2-1 PTHLH
3 mortality/aging MP:0010768 10.11 CHGA DSC3 EGFR FGFR1 KRT5 NCAM1
4 craniofacial MP:0005382 10 EGFR ENO2 FGFR1 KRT5 PTHLH STK11
5 digestive/alimentary MP:0005381 9.98 EGFR FGFR1 KRT5 NKX2-1 PTHLH STK11
6 integument MP:0010771 9.95 DSC3 EGFR FGFR1 KRT5 PTHLH STK11
7 no phenotypic analysis MP:0003012 9.92 CHGA EGFR FGFR1 KRT5 NKX2-1 ROS1
8 normal MP:0002873 9.86 DSC3 EGFR FGFR1 NKX2-1 PTHLH STK11
9 renal/urinary system MP:0005367 9.7 CHGA EGFR FGFR1 KRT7 PTHLH STK11
10 reproductive system MP:0005389 9.56 CHGA EGFR FGFR1 NKX2-1 PTHLH ROS1
11 respiratory system MP:0005388 9.17 EGFR ENO2 NKX2-1 PTHLH SFTPB STK11
Sources

Drugs & Therapeutics for Large Cell Carcinoma

About this section

Drugs for Large Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
2
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
3
Sirolimus Approved, Investigational Phase 4 53123-88-9 46835353 5284616 6436030
4
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
5
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
6 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1
8 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
9 Immunologic Factors Phase 4,Phase 3,Phase 1,Phase 2
10 Immunosuppressive Agents Phase 4
11 Anti-Infective Agents Phase 4
12 Antibiotics, Antitubercular Phase 4
13 Antifungal Agents Phase 4
14 Anti-Bacterial Agents Phase 4
15
nivolumab Approved Phase 3,Phase 2 946414-94-4
16
Crizotinib Approved Phase 3,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
17
Mecasermin Approved, Investigational Phase 3 68562-41-4
18
Tyrosine Approved, Investigational, Nutraceutical Phase 3,Phase 1 60-18-4 6057
19 Mitogens Phase 3,Phase 2,Phase 1
20
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
21 Antineoplastic Agents, Immunological Phase 3,Phase 2
22 Protein Kinase Inhibitors Phase 3,Phase 1
23 Antibodies, Monoclonal Phase 3,Phase 2
24 Antibodies Phase 3,Phase 2
25 Immunoglobulins Phase 3,Phase 2
26 insulin Phase 3
27 Insulin, Globin Zinc Phase 3
28
Docetaxel Approved, Investigational Phase 2,Phase 1 114977-28-5 148124
29
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
30
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
31
Etoposide Approved Phase 2 33419-42-0 36462
32
Cisplatin Approved Phase 2,Phase 1 15663-27-1 2767 441203 84093
33
Bevacizumab Approved, Investigational Phase 2 216974-75-3
34
Lenograstim Approved, Investigational Phase 2 135968-09-1
35
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
36
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556
37
leucovorin Approved Phase 2 58-05-9 143 6006
38
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
40
motexafin gadolinium Investigational Phase 2,Phase 1 156436-89-4 12047567
41
Veliparib Investigational Phase 1, Phase 2 912444-00-9 11960529
42 Pharmaceutical Solutions Phase 2,Phase 1
43 topoisomerase I inhibitors Phase 2
44 Etoposide phosphate Phase 2
45 Topoisomerase Inhibitors Phase 2
46 Vaccines Phase 1, Phase 2
47 Dermatologic Agents Phase 2,Phase 1
48 Photosensitizing Agents Phase 2,Phase 1
49 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
50 Immunoglobulin G Phase 2

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
2 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4 RAD001;Paclitaxel;Carboplatin
3 ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR Failures Completed NCT00404924 Phase 3 ZD6474 (vandetanib)
4 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738 Phase 3 Crizotinib;Erlotinib Hydrochloride
5 ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Participants Active, not recruiting NCT02737501 Phase 3 Brigatinib;Crizotinib
6 Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
7 Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer Terminated NCT00673049 Phase 3 CP 751,871 (Figitumumab);Erlotinib;Erlotinib
8 A Phase II Clinical Trial of Docetaxel, Oxaliplatin Combination Chemotherapy in Patients With Stage IIIB/IV Non-adenocarcinoma, Non-small Cell Lung Cancer (NSCLC) as Second-line Treatment Unknown status NCT01497041 Phase 2 Docetaxel;Oxaliplatin
9 A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer Completed NCT01362400 Phase 2 IPI 504 plus Docetaxel;Placebo plus Docetaxel
10 Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) Completed NCT00240097 Phase 2 Intervention A: Irinotecan; Oxaliplatin; Neulasta;Intervention B: Etoposide; Carboplatin; Neulasta
11 Vaccine Treatment for Advanced Non-Small Cell Lung Cancer Completed NCT00073398 Phase 1, Phase 2
12 Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR Recruiting NCT03110978 Phase 2 Nivolumab
13 Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting NCT01386385 Phase 1, Phase 2 Carboplatin;Paclitaxel;Veliparib
14 Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery Active, not recruiting NCT00334815 Phase 2 Cisplatin;Docetaxel;Etoposide
15 Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT) Terminated NCT01511081 Phase 2
16 Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer Terminated NCT00365183 Phase 2 Motexafin gadolinium and pemetrexed
17 Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146) Terminated NCT00632203 Phase 2 Temozolomide
18 A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) Completed NCT00102505 Phase 1 Motexafin Gadolinium Injection
19 An Open Label Study of a Peptide Vaccine in Patients With Stage IIb or IIIa Non-Small Cell Lung Cancer Completed NCT00054899 Phase 1
20 -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer Terminated NCT01441128 Phase 1 PF-02341066/PF-00299804;PF-02341066/PF-00299804
21 Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer Withdrawn NCT01637376 Phase 1 Temoporfin
22 Use of Social Networking to Survey Women With Small and Large Cell Carcinomas of the Cervix Recruiting NCT01606293
23 CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology Active, not recruiting NCT03940846
24 Mass Spectral Fingerprinting in Lung Cancer Active, not recruiting NCT02781857
25 Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy Active, not recruiting NCT02357992 Not Applicable
26 An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer No longer available NCT02784158 Brigatinib

Search NIH Clinical Center for Large Cell Carcinoma

Cochrane evidence based reviews: carcinoma, large cell

Sources

Genetic Tests for Large Cell Carcinoma

About this section
Sources

Anatomical Context for Large Cell Carcinoma

About this section

MalaCards organs/tissues related to Large Cell Carcinoma:

42
Lung, Breast, Thyroid, Thymus, Ovary, Cervix, Prostate
Sources

Publications for Large Cell Carcinoma

About this section

Articles related to Large Cell Carcinoma:

(show top 50) (show all 169)
# Title Authors Year
1
Comparison of genomic landscapes of large cell neuroendocrine carcinoma, small cell lung carcinoma, and large cell carcinoma. ( 30793508 )
2019
2
The landscape of actionable molecular alterations in immunomarker-defined large cell carcinoma of lung. ( 30978501 )
2019
3
Large Cell Carcinoma with Adenocarcinoma in Lung. ( 29544586 )
2018
4
An Unusually Aggressive Large Cell Carcinoma of the Lung: Undiagnosed until Autopsy. ( 29682432 )
2018
5
BRAF mutations in sarcomatoid and large cell carcinoma of the lung. ( 27939777 )
2017
6
BRAF mutations in sarcomatoid and large cell carcinoma of the lung-reply. ( 27939780 )
2017
7
Serotype-Specific Killing of Large Cell Carcinoma Cells by Reovirus. ( 28587298 )
2017
8
Clinicopathological and genetic characteristics of pulmonary large cell carcinoma under 2015 WHO classification: a pilot study. ( 29246019 )
2017
9
Expression of the CXCR4 ligand SDF-1/CXCL12 is prognostically important for adenocarcinoma and large cell carcinoma of the lung. ( 26818832 )
2016
10
The development of large-cell carcinoma in the wall of a giant bulla complicated by hemorrhage. ( 26964998 )
2016
11
Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung. ( 27384989 )
2016
12
A retrospective analysis of the clinicopathological characteristics of large cell carcinoma of the lung. ( 25452802 )
2015
13
USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma. ( 25519684 )
2015
14
Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal. ( 25620799 )
2015
15
Oxidative stress associates with aggressiveness in lung large-cell carcinoma. ( 25638031 )
2015
16
Close relation of large cell carcinoma to adenocarcinoma by hierarchical cluster analysis: implications for histologic typing of lung cancer on biopsies. ( 25789531 )
2015
17
Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer. ( 25937073 )
2015
18
Prolonged survival with erlotinib followed by afatinib in a caucasian smoker with metastatic, poorly differentiated large cell carcinoma of the lung: a case report. ( 26186355 )
2015
19
Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. ( 26317919 )
2015
20
Frequent loss of the expression of multiple subunits of the SWI/SNF complex in large cell carcinoma and pleomorphic carcinoma of the lung. ( 26345631 )
2015
21
The BCL11A-XL expression predicts relapse in squamous cell carcinoma and large cell carcinoma. ( 26543611 )
2015
22
Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma. ( 23738762 )
2014
23
Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. ( 24221342 )
2014
24
Large-cell carcinoma of the lung: a diagnostic category redefined by immunohistochemistry and genomics. ( 24811836 )
2014
25
Large cell carcinoma of lung: On the verge of extinction? ( 25023633 )
2014
26
Treatment outcomes of patients with different subtypes of large cell carcinoma of the lung. ( 25085555 )
2014
27
Large cell carcinoma on the bullous wall detected in a specimen from a patient with spontaneous pneumothorax: report of a case. ( 25364539 )
2014
28
A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer). ( 24679951 )
2014
29
Urinary bladder urothelial carcinoma with expression of KIT and PDGFRA and showing diverse differentiations into plasmacytoid, clear cell, acantholytic, nested, and spindle variants, and into adenocarcinoma, signet-ring cell carcinoma, small cell carcinoma, large cell carcinoma, and pleomorphic carcinoma. ( 23696935 )
2013
30
Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. ( 23196793 )
2013
31
Acute small bowel obstruction: a rare initial presentation for the metastasis of the large-cell carcinoma of the lung. ( 22284720 )
2012
32
Hypereosinophilia driven by GM-CSF in large-cell carcinoma of the lung. ( 22420949 )
2012
33
Rhabdoid large cell carcinoma of lung, with illustrative immunohistochemical and molecular findings. ( 22505007 )
2012
34
Mixed squamous and large-cell carcinoma of the lung: a case study and literature review. ( 23174733 )
2012
35
Primary undifferentiated large cell carcinoma of the lacrimal gland. ( 21276618 )
2011
36
Pulmonary large cell carcinoma mimicking an infected thoracoabdominal aortic aneurysm. ( 21847044 )
2011
37
Heterogeneity of large cell carcinoma of the lung: an immunophenotypic and miRNA-based analysis. ( 22031317 )
2011
38
Large cell carcinoma of the lacrimal gland diagnosed by fine needle aspiration biopsy. ( 22132846 )
2011
39
Intussusception of small intestine due to metastasis of large cell carcinoma of the lung with a rhabdoid phenotype. ( 20956201 )
2010
40
Curcumin inhibits human lung large cell carcinoma cancer tumour growth in a murine xenograft model. ( 20077433 )
2010
41
Toona sinensis extracts induced cell cycle arrest and apoptosis in the human lung large cell carcinoma. ( 20123594 )
2010
42
Results of surgical resection for patients with large cell carcinoma of the lung. ( 20547250 )
2010
43
Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. ( 19287461 )
2009
44
Large cell carcinoma of the lung and squamous cell carcinoma of the oropharynx presenting as uveitis. ( 19413230 )
2009
45
Cystic tumors of the right atrium caused by nonbacterial thrombotic endocarditis in a patient with large cell carcinoma. ( 19420823 )
2009
46
Large cell carcinoma of the lung: an endangered species? ( 19444077 )
2009
47
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. ( 19996214 )
2009
48
Immunohistochemical characterization of a pulmonary large-cell carcinoma in a dog. ( 18587094 )
2008
49
Hypoglycemia due to paraneoplastic secretion of insulin-like growth factor-I in a patient with metastasizing large-cell carcinoma of the lung. ( 17299065 )
2007
50
Identification of HLA-A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lung. ( 17131342 )
2007
Sources

Variations for Large Cell Carcinoma

About this section
Sources

Expression for Large Cell Carcinoma

About this section
Search GEO for disease gene expression data for Large Cell Carcinoma.
Sources

Pathways for Large Cell Carcinoma

About this section

Pathways related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
12.09 ENO2 NCAM1 NKX2-1 SYP
2
L1CAM interactions 67
Show member pathways
 11.59 EGFR FGFR1 NCAM1
3
Parathyroid hormone synthesis, secretion and action 38
11.36 EGFR FGFR1 PTHLH
4
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 66
11.03 FGFR1 NCAM1 SYP
5
Signal transduction by L1 67
10.12 EGFR FGFR1 NCAM1
Sources

GO Terms for Large Cell Carcinoma

About this section

Cellular components related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.23 CEACAM5 CHGA DSC3 EGFR FGFR1 NCAM1

Biological processes related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 animal organ morphogenesis GO:0009887 9.58 NKX2-1 SFTPB TP63
2 cornification GO:0070268 9.54 DSC3 KRT5 KRT7
3 lung development GO:0030324 9.5 EGFR FGFR1 NKX2-1
4 cerebral cortex cell migration GO:0021795 9.26 EGFR NKX2-1
5 salivary gland morphogenesis GO:0007435 9.16 EGFR FGFR1
6 regulation of phosphate transport GO:0010966 8.96 FGFR1 ROS1
7 epidermis development GO:0008544 8.92 EGFR KRT5 PTHLH TP63

Molecular functions related to Large Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 EGFR FGFR1 ROS1
Sources

Sources for Large Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....